Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: A multicenter, phase II, open-label, non-comparative, extension study in Japan

International Journal of Clinical Oncology

Volumn 18, Issue 2, 2013, Pages 306-313

  Nishimura, Kazuo ^a   Nonomura, Norio ^b   Hashine, Katsuyoshi ^c   Kanayama, Hiro Omi ^d   Ozono, Seiichiro ^e   Miura, Takeshi ^f   Miki, Tsuneharu ^g   Kakehi, Yoshiyuki ^h   Arai, Yoichi ⁱ   Ogawa, Osamu ^j   Fujita, Ryuji ^k   Nonomura, Katsuya ^l   Mizokami, Atsushi ^m   Hoshi, Senji ⁿ   Akaza, Hideyuki ^o  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^h KAGAWA UNIVERSITY   (Japan)

ⁱ TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KYOTO UNIVERSITY   (Japan)

^k IWAKUNI NATIONAL HOSPITAL   (Japan)

^l HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m KANAZAWA UNIVERSITY   (Japan)

ⁿ Yamagata Prefectural Central Hospital   (Japan)

^o UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Castration resistant; Docetaxel; Extension study; Japan; Prednisolone; Prostate cancer

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADRENAL METASTASIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GLEASON SCORE; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; INJECTION SITE REACTION; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LONG TERM CARE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; NEUTROPHIL; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; THERAPY DELAY; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PREDNISOLONE; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84880916697     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0380-1     Document Type: Article

References (19)

1. American Cancer Society (2010). Detailed guide: prostate cancer 2009. What are the key statistics about prostate cancer? http://www.cancer.org/ docroot/CRI/content/CRI-2-4-1X-What-are-the-key-statistics-for-prostate-cancer- 36.asp?sitearea of subordinate document. Accessed March 2011
2. Ministry of Health, Labor and Welfare (2011) Vital statistics in Japan - the latest trends, p 18. http://www.mhlw.go.jp/english/database/db-hw/dl/81- 1a2en.pdf of subordinate document. Accessed March 2011
3. Suzuki K (2009) Epidemiology of prostate cancer and benign prostatic hyperplasia. JMAJ 52:478-483. http://www.med.or.jp/english/journal/pdf/2009-06/ 478-483.pdf of subordinate document
4. Ringel I, Horwitz SB (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291
5. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
6. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
7. Chowdhury S, Burbridge S, Harper PG (2007) Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 61:2064-2070
8. Goh BC, Lee SC, Wang LZ et al (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
9. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114
10. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38:365-372
11. Chin SN, Wang L, Moore M et al (2010) A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 17:24-29
12. Beer TM, Garzotto M, Henner WD et al (2004) Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 91:1425-1427
13. Miller K, Wuelfing C, Lehmann J et al (2005) Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: preliminary results of a multicenter phase II study (AUO AP33/02). J Clin Oncol 23(16S Pt 1 Suppl):406s (abstract 4613)
14. Beer TM, Ryan CW, Venner PM et al (2008) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer (Phila) 112:326-330
15. Ansari J, Hussain SA, Zarkar A et al (2008) Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 20:891-896
16. Soga N, Kato M, Nishikawa K et al (2009) Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol 14:130-135
17. Di Lorenzo G, Buonerba C, Faiella A et al (2011) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 107:234-239
18. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154
19. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005